C-RAD announces a significant milestone in the field of particle therapy with an order from the proton therapy market leader Ion Beam Applications S.A. (IBA) for 10 Catalyst+ PT and…
Read More
Agreement at a value of 16 MSEK signed between C-RAD and customer in North Rhine-Westphalia, Germany
C-RAD is re-confirmed as a partner for outstanding radiotherapy by a clinic in North Rhine-Westphalia, Germany. A C-RAD customer in North Rhine-Westphalia, Germany decides to expand the existing SGRT solution…
One of the most accomplished cancer programs in the U.S., Atrium Health Levine Cancer, is scheduled to open its new Atrium Health Proton & Advanced Radiation Center in late 2023….
Katholisches Klinikum Bochum gGmbH – St. Josef Hospital in Bochum, Germany, has decided to use the C-RAD SGRT solution in its modernised radiotherapy. The order, which has a value, before…
During 21 August 2023 and 23 August 2023, C-RAD AB (publ) (LEI code 549300SPXLHF15W2CU25), has repurchased in total 28,500 own B-shares (ISIN: SE0002016352). The repurchase is carried out in accordance…
During 15 August 2023 and 18 August 2023, C-RAD AB (publ) (LEI code 549300SPXLHF15W2CU25), has repurchased in total 60,000 own B-shares (ISIN: SE0002016352). The repurchase is carried out in accordance…
C-RAD continues to advance treatment capabilities focused on breast cancer treatment by collaborating with Accuray on their new VitalHold™ Breast Solution for the Radixact® System. The VitalHold technology will be…
The Patent and Market Court of Appeal issued a judgment on 30 June 2023 regarding a claim for compensation from a former employee for C-Rad's use of an invention. The…
Second quarter April – June 2023 · Order intake increased 12 percent to 117.8 (105.6) MSEK (2 percent in constant currencies). · Order backlog amounted to 679.1 (498.6) MSEK. · …
Following the mandate from the Annual General Meeting held on May 5, 2023, the Board of Directors of C-RAD AB (publ) has decided to repurchase own shares The reason for…